Cargando…
Antagonism of Sorafenib and Regorafenib actions by platelet factors in hepatocellular carcinoma cell lines
BACKGROUND: Platelets are frequently altered in hepatocellular carcinoma (HCC) patients. Platelet lysates (hPL) can enhance HCC cell growth and decrease apoptosis. The aims were to evaluate whether hPL can modulate the actions of Sorafenib or Regorafenib, two clinical HCC multikinase antagonists. ME...
Autores principales: | D’Alessandro, Rosalba, Refolo, Maria G, Lippolis, Catia, Giannuzzi, Grazia, Carella, Nicola, Messa, Caterina, Cavallini, Aldo, Carr, Brian I |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4038078/ https://www.ncbi.nlm.nih.gov/pubmed/24885890 http://dx.doi.org/10.1186/1471-2407-14-351 |
Ejemplares similares
-
Chlorogenic Acid Improves the Regorafenib Effects in Human Hepatocellular Carcinoma Cells
por: Refolo, Maria Grazia, et al.
Publicado: (2018) -
IGF-1R tyrosine kinase inhibitors and Vitamin K1 enhance the antitumor effects of Regorafenib in HCC cell lines
por: Refolo, Maria Grazia, et al.
Publicado: (2017) -
Resistance to multikinase inhibitor actions mediated by insulin like growth factor-1
por: Lippolis, Catia, et al.
Publicado: (2015) -
Platelet extracts induce growth, migration and invasion in human hepatocellular carcinoma in vitro
por: Carr, Brian I, et al.
Publicado: (2014) -
Ramucirumab and GSK1838705A Enhance the Inhibitory Effects of Low Concentration Sorafenib and Regorafenib Combination on HCC Cell Growth and Motility
por: D’Alessandro, Rosalba, et al.
Publicado: (2019)